ABVC BioPharma, Inc.
ABVC
$1.23
-$0.08-6.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -200.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -200.00% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -200.00% | -- | |||
| SG&A Expenses | 12.17% | -14.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -59.09% | -- | |||
| Total Operating Expenses | 11.88% | -14.50% | |||
| Operating Income | -156.51% | 49.19% | |||
| Income Before Tax | -196.22% | 44.27% | |||
| Income Tax Expenses | -100.00% | -97.88% | |||
| Earnings from Continuing Operations | -196.11% | 44.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 508.54% | -45.91% | |||
| Net Income | -185.83% | 44.77% | |||
| EBIT | -156.51% | 49.19% | |||
| EBITDA | -157.29% | 49.29% | |||
| EPS Basic | -168.84% | 58.71% | |||
| Normalized Basic EPS | -106.69% | 59.22% | |||
| EPS Diluted | -174.44% | 58.71% | |||
| Normalized Diluted EPS | -106.69% | 59.22% | |||
| Average Basic Shares Outstanding | 6.35% | 33.76% | |||
| Average Diluted Shares Outstanding | 6.35% | 33.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||